Adults with primary membranous nephropathy achieved higher complete remission rates with obinutuzumab than tacrolimus in the pivotal phase 3 MAJESTY trial.
Researchers have uncovered a new way to attack lymphoma by targeting a non-catalytic region of a key regulatory enzyme, rather than its traditional active site. Researchers at VCU Massey Comprehensive ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s ABBV combination treatment for chronic ...
Bayer proposes a $7.25 billion settlement to resolve Roundup lawsuits over non-Hodgkin lymphoma, expanding its legal ...
Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using ...
The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...
Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...
Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
Myasthenia Gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and muscles. This attack causes ...
Interest in the use and impacts of glucagon-like peptide-1 receptor agonists in rheumatology has exploded over the past year, a trend that appeared to crescendo at ACR Convergence 2025. There, ...
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results